New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever
(WorldNews Health)

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.1 These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Conference.1 The trial compared Symbicort Turbuhaler with two commonly used treatment regimens in mild asthma. In real-world practice, patients typically use a short-acting beta2-agonist (SABA) reliever in response to symptoms or daily low-dose inhaled corticosteroid (ICS) maintenance therapy with a SABA reliever. In this...